Demant A/S (DEMANT) Earnings Call Transcript
August 12, 2026
Earnings Call Speaker Segments
Good afternoon, everyone, and welcome to the conference call covering Demant's interim report for 2026. I'm Peter Pudselykke, and I head up Investor Relations here at Demant. Joining me today are the folks you're used to: Søren Nielsen, our President and CEO; René Schneider, our CFO; and one of my good colleagues on the IR team, Gustav H. By now you should have seen that a couple of announcements went out from us last night: one about the interim report and one about the launch of our new premium hearing aid, Oticon Reveal. Both of those will be covered during today's call, and we plan to begin with a presentation, after which we'll move to a Q&A session. The whole session should run no longer than 1 hour, and the presentation ought to be online by now. Once we reach the Q&A, we kindly ask you to keep to two questions at a time, please, so that as many people as possible get a chance to ask. Before we dig into the presentation, please do take note of the disclaimer slide on slide 2, and with that, on to slide 3, where I'll hand things over to Søren to start with the agenda, please.
Thanks so much, Peter, and welcome, everyone. Here's today's agenda: no surprise, the highlights and financial takeaways, and a review of the big business areas. René will walk us through more detail on the group financials, discuss the outlook or present the revised outlook, and take Q&A. Highlights for the first half of Demant 2026: strong momentum across all business areas, ahead of expectations, with growth picking up from the first quarter into the second. That's driven by strong performance in Hearing Aids, where, fueled by the success of Oticon Zeal, we've seen momentum strengthen further. Market growth continues to be in line with what we saw in the first quarter, but at the higher end of what I'd call our lower-than-normal expectations. In Hearing Care, we've seen very solid execution and, of course, a significant contribution as well from the acquisition of Kind, which, all in all, has delivered very strong performance — Kind not least. The cost-saving initiatives announced in February 2026 are progressing ahead of plans and supporting underlying margin improvements. René will go through that in more detail. The divestment of the implant and communications business was completed in Q1, and we are now a fully focused hearing healthcare company.
Here's how I'd frame the main financial points from the first half. At group level we saw 15% reported growth, with solid momentum across every business area, and 10% of that came from acquisitions — mainly Kind, though other deals contributed as well. One thing worth highlighting is the gross margin, which rose 1 percentage point, helped by a favorable mix of geography, channel, and product within Hearing Aids, which drove strong ASP, and further supported by the Kind acquisition in Hearing Care. The retail side of Hearing Care structurally carries a somewhat higher gross margin than wholesale, so naturally the mix lifts it too — but I'd add that it came in above what we had expected. Organic OPEX was up 5%, partly helped by the cost-saving initiative we announced earlier in the year, back in February. Acquisitions, chiefly Kind, contributed 14% to group OPEX. EBIT before special items reached 2.134 billion Danish kroner, equal to a 16.5% EBIT margin. Beyond that, René will go into detail on the strong underlying performance gains and the underlying margin improvement as well. Cash flow was robust: 1.6 billion from operations, which is a 6% increase versus the first half of '25. Given how we performed in the first half and our fresh assessment of momentum and the second-half outlook, we have raised our financial outlook for 2026.
Organic revenue growth is now projected at 6% to 7%, with EBIT before special items at 4.4 to 4.8 billion Danish kroner. Turning to the business areas, beginning with Hearing Aids: for the global hearing aid market in first half 2026, our estimate is 4% growth in value and 3% in units. Unit growth in the second quarter looks somewhat different from the first quarter, with US commercial at 0% and US VA at 1%. That's lower than the first quarter, though the comps differ as well — 30,000 feet unchanged market conditions, still under the normal expectation of 4% to 6%, but somewhat more positive on ASP development, where we normally expect flat, we've seen and estimate improved pricing of 1%, also in the second quarter. On second quarter highlights by geography, growth in Europe was driven by Germany and France, while NHS was negative. That's purely because of purchase phasing there. Excluding the UK, Europe posted 6% growth, quite solid. In North America, as I already mentioned, flat or modest growth in North America depending on channel. Canada delivered strong growth. Rest of the world, we estimate — we have no statistics there, but our estimate is that China kept some positive momentum despite persistently challenging market conditions.
Down in Australia, we’ve likewise seen growth turn positive again after a soft Q1 — though, once more, take that with a grain of salt, since it depends on how last year was phased. Overall, market conditions look consistent with what we observed in the first quarter. Turning to Hearing Aids in the second quarter: growth accelerated further, powered by the full rollout of Oticon Zeal across every channel and geography, and that produced 10% growth. I’d call it broad-based. Zeal is, yes, in many respects the spearhead behind that growth and the shift in momentum, but we’ve genuinely seen a nice, broad pickup — most notably in North America, where we posted double-digit growth, clearly well ahead of underlying market growth; also strong in Canada, solid in Germany and the UK, with France and Spain also growing strongly; and in Asia-Pacific, the highlights are Japan and, to some extent, Australia, while China recorded negative growth mainly because of challenging market conditions. As Peter mentioned, we also put out news yesterday that we’ll be launching very soon our new flagship product, Oticon Reveal, our latest innovation, and I’ll share a few highlights on the core technology that now lifts hearing aid performance to a new level.
We're launching the first dual AI system in the world, and what's at its heart? At its heart is this: up to now, most AI systems — arguably all of them — have revolved around attempting in some manner to detect noise and suppress it, more or less depending on your philosophy. Now we've introduced a second, parallel AI system that concentrates on speech — the content of that speech and its details — so you could say the contrast, the clarity of the speech, gets enhanced further. These 2 systems run in parallel, though of course they're synchronized and optimized relative to each other, and altogether they operate as a single system in real time, all the time, very strong. A brand new Reveal AI platform powers this. It's still built — as we've done things for a number of years now — to support how the brain makes sense of things, how we translate from what comes in to what it means, to what is actually being said, so that we can respond and enjoy what we hear. The first dual AI system in the world supports speed, precision, balancing of things. Part of that: one thing is knowing what you want to do very fast and being able to adjust the gain very precisely in the instrument, but if you don't have a very strong anti-feedback system — meaning the microphone ends up hearing the speaker — then you simply cannot deliver the gain.
Our feedback prevention system is now substantially better, and we can provide considerably more gain with greater speed and higher precision than we think any rival can come close to. In practice, this matters a great deal for the benefits delivered to the end user as well, since it is frequently about supplying plenty of gain for soft sounds, so once again you pull the small details out of things. Then there is a new connectivity platform too, which delivers even greater stability and longer range; users can again take pleasure in the link to the phone even when that phone sits quite far away and essentially hear it ring or enjoy music, whatever the case may be. With this dual AI system, which forms the heart of it, all of this comes from a new platform — one that remains built on our philosophy and rests on a single chip. That is a major advantage for power consumption, for size, for integration level, and optimizing it lets us run the two AI systems in parallel without wrecking power consumption; the features stay on at all times, operating seamlessly for the end user. There is no cap on how much time you can spend in noise or on how many hours or minutes you can use it; these features are always active and will help you achieve unmatched precision of speech and unmatched clarity in noisy environments, while also preserving a degree of contextual sounds so that you actually know whether you are in the restaurant or in traffic or wherever you happen to be.
The evidence supporting these benefits is extremely robust—some might even call it a bit scientific in nature—but that rigor exists to guarantee things genuinely deliver. We observe a highly meaningful gain in the signal-to-noise ratio delivered to the end user, achieved not by removing anything but by rebalancing elements differently. There's a very substantial boost to what's known as the speech intelligibility index—in other words, how well I can actually comprehend and interpret what's being said. When the brain is truly able to see or hear the signal and derive meaning from it, we witness a very strong response. That is measurable, and we observe a highly meaningful improvement—corroborated by our trials as well—relative to Oticon Intent, which I believe everyone would agree is already a highly capable hearing aid and platform. Oticon Reveal delivers very strong comfort and will bring excitement to the market plus meaningful benefit for end users—whether this is your first hearing aid or an upgrade from an already well-performing premium product built on the newest technology, you will experience a meaningful improvement in benefit. Within Hearing Care, the second quarter showed very strong performance, with a meaningful contribution from Kind. In local currencies, growth reached an impressive 31%, of which 23% stems from acquisitions—chiefly Kind, plus a larger UK acquisition completed in March; organic growth for the quarter was a strong 8%, helped somewhat by last year's comparatives but also reflecting sequentially an uplift in business momentum and strong execution across geographies broadly.
Kind performed well on its own, and we specifically call that out too — which is great for scale and profit, obviously, and it's also nice to see now that the uncertainty around the immediate takeover has cleared. We feel very good about the added upside of having Kind within our group. Geographically, we saw strong results across the region, especially in Germany, along with several other markets. Growth was somewhat lower in France, though that reflects how the distribution system keeps expanding there, with a number of new players entering the field. It was strong and driven by both the US and Canada. In the US, growth benefited from somewhat easier comparables than we faced in Q1. We all recall the uncertainty last year stemming from, let's say, political uncertainty. In Australia we had strong organic growth, while China showed negative growth, driven by difficult market conditions as well as tough comparables. Some reimbursement was released last year that no longer exists, which has clearly reduced both product mix and demand. Diagnostics in the second quarter: very strong performance, and we're very, very pleased to see a return to solid growth rates in the quarter at 9%.
Once more, in Q2 of last year uncertainty was extremely high, and we witnessed considerable hesitation when it came to executing orders—partly because of that, of course—but we also definitely sense better momentum and that we are gaining share, and growth came from both instrument sales and the service and consumable business. Growth was, well, broad-based, yet especially strong in the UK, but also the US, Canada, and so on. All in all very good. René, over to you for the group financials.
Thank you, Søren. Turning to revenue for the first half — this will be a bit repetitive. Organic growth was broad-based at 7% in the first half, while acquisitive growth came in at 10%, all of it tied to acquisitions in Hearing Care — mainly Kind, of course, plus a larger retail business in the UK and some smaller bolt-ons. FX had a negative impact of 3%, driven by the US dollar, giving total reported revenue growth of 15%. One highlight from the first half is how gross profit developed. It rose 17% to just under 10 billion, and the margin expanded 1.1 percentage points compared with last year, which came in ahead of what we expected. The main drivers were a very healthy, solid ASP development in Hearing Aids, reflecting strong mix across geography, channel, and product, but equally supported by a strong contribution from the Kind acquisition and its performance in Hearing Care. That takes us to operating expenses and EBIT. We delivered 5% organic growth in the first half, which was partly helped by our cost-saving initiatives but also included negative one-offs tied to the restructuring of retail in the UK, which I will return to.
When it comes to acquisitions, mainly Kind again, that contributed 14% to OPEX growth, while exchange rates had a negative impact of 2%. Turning to EBIT before special items, it came in at 2.134 billion, which corresponds to a margin of 16.5%, or 19% growth in local currencies. Within that result and within that margin, we've absorbed a number of negative effects — one being an estimated 50 million negative impact from exchange rates, plus an additional 30 million kroner stemming from the acquisition of a larger retail chain in the UK and the restructuring carried out during the first-half year as part of our operating profit. Excluding that, underlying EBIT margin expansion would have been 0.6 percentage points versus last year, which reflects strong underlying operating leverage. Special items in the first half totaled 216 million, mainly related to Kind. That strong first-half result also means that, when we discussed the outlook for the year earlier, we pointed to a back-end loaded EBIT profile for the year. With this result, we now see a more normal phasing of EBIT across the two half-years. Cash flow was strong, both in terms of cash flow from operations and free cash flow.
I'd point to the net cash inflow from acquisitions and divestments — while we've made acquisitions, the divestments completed over that same period actually leave us with a net cash inflow of 91 million. As you probably know, no share buybacks were carried out in the first half, since our focus has been on bringing down debt and leverage, which leads us to balance sheet development and net interest-bearing debt. On the right-hand side of the graph, you can see the spike in leverage following the Kind acquisition, but you can also see the strong deleveraging achieved since then — in fact we're ahead of plan on deleveraging, thanks to both strong cash generation and profit growth. We now stand at 3.0, and our updated view on gearing is that by end of 2026 we expect to be slightly above the 2 to 2.5 range, which is our long-term guidance. With that, let's move on to outlook. A brief comment on the market. I'd say it's almost as normal, but we do base our market understanding on a competitive environment where we know competitors, or expect competitors, to launch new product in H2, and that is built into our assumptions.
Given how the hearing aid market performed in H1, we're revising our full-year assumptions to 3% to 4%. That remains a cautious figure, sitting below the medium- to long-term fundamental assumption we hold for the market. A few things to flag: on special items, we've adjusted the total to 400 million now, up from 325. We've pushed hard on both the Kind integration and the cost-savings initiatives, and because of that, we're also seeing higher special items. Kind integration special items are now estimated at 150, up from 125, and cost-saving initiatives now stand at 250 million, up from 200 million, primarily all tied to severance payments and implementation costs. The other highlights on the outlook side include a less negative FX effect, as you've seen in the announcement, plus higher profit contribution from both CEI and Kind. The cost-effectiveness program is now estimated to contribute 300 million versus 250 in the original outlook, and with the better performance in Kind, we expect a contribution to EBIT of 325 million, up from 300 million. Lastly, though more minor, we expect a refund of tariffs in H2 of 25 million. With that, to sum up, our outlook is now 6% to 7% organic growth and an EBIT before special items in the range of 4.4 to 4.8 billion.
With that being said, we're all set to move on to the question-and-answer portion.
Thanks. We’re moving into the Q&A portion now. If you’d like to ask something, press star followed by one on your phone’s keypad. When you’re on a speakerphone, lift the handset first, then press the keys. Should your question get answered at any point and you want to pull it, press star then two. Kindly keep to two questions per turn so other people have a chance to ask. We’ll take a brief pause right now while we put the roster together. Our first question is from Martin Parkhøi at SEB. Go ahead, please.
Yes, good afternoon. This is Martin Parkhøi from SEB, with a couple of questions. First one concerns Hearing Care: given the 8% organic growth posted in Q2, and knowing that a strong ASP uplift contributed there, helped of course by Zeal's high price point, how should we think about the ASP contribution across the rest of the year in Hearing Care? Zeal will of course still be a year-over-year benefit, but could there be some effect once lower-priced versions of Zeal come to market as well? My second question is also about pricing, though at the wholesale level: first, you've achieved fairly solid success with Zeal's premium pricing. What are your plans for Reveal as against Intent at each tier? And from an industry standpoint, how do you see the pricing risk in the second half, given the rather crowded launch window the industry has right now? Some players may be more desperate than others to use these new products to drive growth.
Thanks, Martin, for that. It's accurate that a meaningful ASP component exists within Hearing Care's growth. Part of that stems from geography mix, yet mostly it comes down to product mix. Yes, Oticon Zeal has likewise proven a big success in own retail, but naturally it's also generally what we focus on to help more people obtain a better solution, and that differs somewhat from market to market based on reimbursement and so forth. Regarding the second half, yes, I believe we ought to be able to sustain it, and in own retail we consistently observe that whenever we launch exciting new technology at the premium level, the upgraded portion of the business tends to rise. That will certainly be a focus with Reveal, whereas Oticon Zeal, you might say, centers more on first-time users. Both will work together, and I believe each will be among the elements supporting continued favorable ASP development in own retail as well. On the hearing aid wholesale side, I'd put it this way: the more premium introductions there are, the more you tend to witness — for the same upgrade-related reason — positive product mix development across the industry.
So if there ends up being a bigger or smaller discount on the new models, well, I still think that in the end, net-net, it leads to an improved product mix that outweighs things, even if that effect shows up. At least to start with, I believe everyone will aim to earn a return on what they've put into R&D; I'd say that's the normal approach, and even when we see a lot of it, it's beneficial for the ASP during that period. Our own expectation is certainly that we'll see it, though not to the same degree as with Zeal, since that product was extremely unique and, you could almost say, had no competition — but Reveal should also make a net price increase possible relative to Oticon Intent.
Thanks.
Thanks. Our following question is from Veronika Dubajova at Citi. You have the floor.
Good afternoon, everyone, and thanks for taking my questions. I have two, please. First, Søren, I was hoping you might give us some flavor around the run rate for Zeal and how you're thinking about further growth opportunities from here, whether in terms of lower price points or geographies, and just how much more room you feel there is for Zeal to keep driving a meaningful contribution to growth, as seems to have been the case in the first and the second quarter of the year. Then my second question is really about your thought process on Reveal and how it might position. Obviously, I know we're still waiting for two more product launches, but it would be really helpful to understand, from an AI perspective, from a size and battery and power perspective, what you think Zeal brings to the table that you don't see in the market right now or aren't anticipating from folks as you look at the launch window. Thanks so much.
Thanks so much, Veronika. From a growth standpoint, I'd certainly say that with Zeal we're still comparing against 0, so there's of course still meaningful growth coming from Zeal, but on a sequential basis as well, I definitely see additional opportunities. You brought up the example of adding more price points to reach other market segments. I'd say that's probably more of an opportunity in Europe. In North America, there are still channels that don't offer this kind of technology that could come in. There are definitely still—in VA, I would point to significant opportunities. I think several of you asked whether Zeal was a niche product for a niche. We've now clearly seen both an expansion in the number of people who end up with an in-ear rechargeable product. We've also seen Oticon Zeal in that growing segment take very significant share very quickly, and it hasn't come to an end. We also see it as the door opener to clinics we haven't worked with, because obviously to everyone this is a significantly different product, and it offers a chance to both have fantastic outcomes and also the opportunity for what you could call an instant fit, because you can use it with a dome, which means you skip a number of revisits for impression taking and custom shell making, etc.
Far — 3 months into VA, a very positive outcome, and we definitely believe that channel will keep growing, as an example, but also outside for Oticon Zeal. On Reveal's position, I would say it's second to none. Nobody else has managed to combine AI opportunities for both noise and speech being available all the time, at any given time, in an ordinary miniRITE form factor, rechargeable, full connectivity, and everything. For now, from what we can see — and yes, I don't have transparency either to new launches, and that might change it — but with the current competitive situation, what we know and have seen being presented to the market, I think Oticon Reveal is second to none.
That is really useful, thank you. I’ll return to the queue.
Thanks. We'll take the next question from Martin Brenøe at Nordea. Go right ahead.
Hello Søren and René. Thanks for fielding my questions. I'll begin with a pair of questions as well. The first is also about Zeal, to start. You've brought up new price points several times during this call, and I'm somewhat curious whether you believe you've gained an advantage from being more or less the sole new product launch in H1, which might make it somewhat harder to stand out as we move into H2 with additional launches on the way. Could you say a few words about the toolbox available to you for capitalizing on the momentum behind Zeal? Is it the new price points we'll be seeing, or is it more that you'll run a second-wave marketing push on Zeal, or what opportunities do you actually have for building on this momentum as the space becomes more crowded? That's the first question. The second concerns the margin side. Once we adjust for the sizable cost initiatives whose benefits you'll reap in H2, the underlying EBIT margin doesn't really suggest any margin expansion, despite the substantial growth you should be seeing and are also guiding for here.
Is that meant to be a conservative assumption baked into your guidance, or are you in fact putting money back into OPEX based on the run rate you're seeing so you're ready for 2027? That's my second question. Thank you.
Thank you very much, Martin. I believe I brought up new price points once already, but let me draw attention to several European markets where you basically have a narrow premium segment, and we've made very strong inroads there. We've actually broadened it. Our own retail shows us that a growing number of people are prepared to pay, yet it remains a small category. If Zeal — which is what we're aiming for — is truly going to develop into a new method of producing and manufacturing in-ear instruments, we also need more volume flowing into the technology and the business, and so a conversation about additional price points in chosen markets makes sense. Zeal's greatest advantage is that it assists in opening new doors; it will remain a substantial element of our sales efforts, and salespeople's work will involve using both Oticon Reveal and, just as importantly, Zeal, to start a dialogue with customers for whom Oticon is currently a third or fourth supplier, or perhaps not a supplier at all. For our existing customers — those who've already done some business with Oticon — this is now, I'd say, largely familiar material. There's also always training where you can do more, and so forth. We'll put a bit more into media spend on the consumer side as well, to help ensure we keep seeing end users who are aware of the concept and who come into stores asking for it.
This isn't a large volume, but it does matter. There are plenty of levers available for that. On your margin question, I'll begin, and René can add to it, but the cost-saving programs are aimed at lifting the margin on Demant, and that effort is progressing well. Naturally, we have also consistently stated that we will keep investing in the business. We see it as a growth business, yet the ambition is clear, and again, as René just walked you through, there is also a meaningful EBIT margin improvement underlying the first half, and I think there is solid visibility for further improvement in the second half for several reasons. René, perhaps you would like to add a few words?
There isn't a lot to add. You can work the numbers out in plenty of ways, and the range in our outlook accounts for a lot of scenarios, I'd say. What we're working on the assumption of — and it's certainly what we're pushing hard toward — is margin expansion both on a sequential basis and compared with last year, whether you look at reported or underlying figures, in any way you can imagine, and that's what we're planning for. I'd say the outlook we have is one we're very confident in.
I appreciate it.
Thank you. Our next question is from David Adlington at JPMorgan. You have the floor. Hello,
Thanks for taking the questions. Maybe to start, one that's a bit more conceptual. You've tightened the top-line range by 3 points, from 3% to 6% and now to 6% to 7%, which is still a fairly wide band of 400 million, the same as at the beginning of the year. I was just wondering why you hadn't narrowed the EBIT range, and what the differences are between the low and high ends of that range, given the fairly narrow revenue assumptions. Thanks.
Broadly speaking, when markets or specific geographies are performing either extremely well or extremely poorly, we tend to see a fairly high flow-through from revenue changes to EBIT. That's what we've observed before — it reflects the fact that 6% to 7% is really 5.5% to 7.5%, and the corresponding EBIT translation we see likewise amounts to a range of 400 million kroner. The major swing factors are, of course, as I said, the market, and then, relatively speaking, our own anticipated overperformance relative to that market. I'd say this is consistent with the way we've approached things previously.
One quick follow-up on that: did any pre-investment tied to the new launch occur in the first half? No,
Not really.
Should we expect you in the second half? Yep,
Naturally. Nothing unusual, naturally, when you set it against last year. That also feeds into the perhaps somewhat elevated OPEX for this year compared with what you might expect given the cost initiatives and so forth. On the Hearing Aid Wholesale side, it is a heavy launch year, with two major launches and plenty of news to handle. Naturally, we are putting investment behind that as well to ensure we reap the rewards.
To offer a bit of guidance on the OPEX line, on one side, as Søren noted, we're directing substantial resources toward a high-end launch, and you could also say marketing initiatives in Hearing Care, to back the growth and the gross profit push. On the other side, we're likewise carrying out cost effectiveness, so on balance, you'd anticipate an organic growth rate in OPEX perhaps comparable to what you observed in the first-half year.
Great, thanks a lot.
Thanks. Our following question is from Niels Granholm-Leth at DNB Carnegie. The line is yours.
Thanks. I have a couple of questions about the market. First, from your perspective, what would it take to get growth back to normal in the US commercial market? Second, why do you believe pricing discipline has been stronger in this first half? A lot of end-of-life products have been on the market, yet pricing discipline still appears to have held up pretty well.
Thank you, Niels. I can't say when we expect it to normalize, but I think it's worth highlighting that underneath the flattish growth in US commercial, we do still see the managed care segment declining, and we do see cash pay, private, independents have some growth, and then we see the strongest growth being in what we would call big-box retail and large operators, including ourselves. I think it would have to come with a new stand on managed care, and it findings its new balance, and then we would see the total market return to growth. There continue to be some, yeah, drop out, people that are not eligible, whatever it is that drive it, leaking to the other channels, but at some stage, I would assume there is a rebalancing. When that happen is very difficult to estimate, of course. There's no doubt we still see the expected growth in senior population, prevalence of hearing loss, etc. I don't think we have any other indication that this still relates to consumer confidence in general, fear of inflation or inflation for many, and some managed care contracts not offering benefit to the same number of clients as they did in the past.
On the second point, pricing discipline: I could flip that around and note that at least two or three of the players have come out with meaningful innovation, and there's a cost element attached to that as well. So my sense is that the discipline this time may actually have begun with the realization that, to earn a return — and also to defend against the continued rise in cost of goods sold driven by technology, whether that's the production methodology or extra electronics or whatever it might be — at some point you have to say we need to put a stronger pricing discipline in place, and also make a stronger case for the benefit to the end user; otherwise, we've only done it for our own sake. At least I can speak for Demant, but it appears a number of competitors are seeing similar trends and so have been firmer that margin dilution cannot happen, and therefore have been more disciplined around pricing of the premium products, I would say in particular.
I appreciate that.
Thanks. We'll take our next question from Richard Felton at Goldman Sachs. Go right ahead.
Thanks, good afternoon. Two questions, please. First, the in-the-ear category really does appear to be expanding considerably faster than the market as a whole. Could you expand a bit on what you're observing in the interplay between in-the-ear and share gains coming from other form factors, or anything you might be seeing when it comes to category expansion that in-the-ear is driving? Then the second one, Søren, you said Zeal served as the spearhead for growth, yet the remainder of the portfolio is performing well on top of that. Could you perhaps go into why that happens in practice? In what way is Zeal assisting the rest of the portfolio? Thank you.
Thanks so much. Across quite a few markets, we don't have much data on the various styles, though in certain ones we do. It's quite clear that the absence of rechargeability in reasonably sized devices, I'd argue, served as a constraint for a long stretch of years as to why receiver-in-the-ear took off once they'd gained popularity purely for the aesthetic advantage. The receiver-in-the-ear was far less noticeable than the traditional molds. After that came connectivity. After that came rechargeability. There are currently a few concepts out there that, you'd say, genuinely solve that. Zeal, specifically, additionally solves the aesthetic piece, and so essentially delivers nearly identical advantages to a behind-the-ear, which to some looks more conspicuous. That, I believe, is the organic progression and the swing back. New users, when they show up as first-timers, are quite conscious of what's available. They may have spotted a device like this one or that one, and so appearance counts for a great deal, while people already using aids may be somewhat more discerning and even-handed about whether they pick one version or the other. If you've worn a miniRITE for a long stretch of years, I doubt you'd switch to an in-ear product, yet among first-time users it certainly is, for a lot of them, the more appealing option.
When I say spearhead for growth, what I mean is that Zeal acts as a door opener. It's a brand-new concept. You can see the concept, and you see what first-time users get out of it. As I believe I've mentioned previously, there are simply more calls being scheduled with customers where you have little or no business today. From that call, once you have actually fitted one, you get to know the fitting system, you see the quality and also the signal processing, and there's a possibility that you then also succeed in opening up a broader portion of the portfolio to these new customers. That's what I'm getting at when I speak of a spearhead for attention, a spearhead for new opportunities.
Thanks. Our next question is from Kavya Deshpande at UBS. Go ahead, please.
Good afternoon, and thanks for taking my questions. My first one concerns the timing of the launches. Clearly, this platform cycle has run a bit longer than the ones we've seen before. Beyond the dual AI software, could you point to any other key improvements that this additional time has made possible, especially on the hardware side and with the chip, compared with the Sirius chip on the Intent? My second question: Zeal launched on that same chip and keeps many of the same features as Intent. Would the performance gains you've delivered on the Reveal also find a place on a future Zeal model? Is that feasible, and should we be expecting something along those lines? Thank you.
Thank you very much. Yes, we want to highlight two additional major contributions to improvements and innovation. I mentioned this regarding the anti-feedback system, and one might assume that better feedback prevention is a problem we solved long ago, since you no longer hear whistling in the hearing aid. But really, the way to look at it is, if you will, measuring the gain you can actually deliver in a dynamic environment. And we can plainly observe — both in our own past instruments and in competitors' products — that there's effectively a ceiling beyond which the gain cannot rise. You can see the instruments trying to do more, yet being held back. Our new feedback system does two things: it permits more gain, because it can eliminate the loop it generates faster, and it is far more precise, so the gain truly available is considerably higher. That is also a crucial instrument for getting these systems to work in tandem: the AI system screams and calls for something, and then it is actually available too, whereas most other systems are much slower — and by the time the gain is perhaps ready, the need has already gone.
That's a really major innovation and step forward. The second one is connectivity. We've essentially introduced a brand-new connectivity platform in there, and it guarantees, you might say, even stronger perceived reliability of the connection. You drop it far less often, what comes through is of better quality, and the distance you can be from your phone before things deteriorate is far greater — that's also a substantial improvement. On your final question, yes, after this launch, over the period ahead, it's of course only natural that the remainder of our portfolio moves onto this new platform, and at some point that will apply to Oticon Zeal as well. At the moment, we're very pleased with how it performs. It's a new instrument, and the key breakthrough again is of course what it does, but also how it looks; it won't be a major setback for Oticon Zeal that we now have a new miniRITE platform on the market.
Got it. Thanks a lot.
Thanks. Our next question is from Carsten Lønborg Madsen at Danske Bank. You have the floor.
Thanks a lot. First off, a question for René. Regarding that negative 30 million on EBIT tied to integrating the UK retailer — does that represent the entire EBIT contribution? Surely it must have been generating positive EBIT as well, or was it purely the integration cost? That ties into the second part of my question too, which is: how much will it add in terms of EBIT during the second half of the year? Then I have another question after that.
The 30 I mentioned represents the overall net impact on EBIT — a negative 30 million. I'm not breaking that down into sales, cost of goods sold, and OPEX; the net effect on the bottom line comes to 30 million. That's the way to read it: because it was announced in H1, it's behind us, and we expect the business to contribute positively to EBIT in H2. Maybe
To add to that, what we're dealing with here is really a classic scale problem. The absence of profitability in the business we've acquired stems from having too small a headquarters operation, and as a result we see a bit of a collapse of the network, better utilization of the audiologists, but above all, a single headquarter serving a much larger network — and that very quickly gets our business to profitability.
Thanks. Moving to the second question: one of your competitors announced today that they're losing a fairly large managed care contract in the US starting January 2027. So a quick question — do you see any way this could become a tailwind for Oticon in 2027, with that contract being reallocated?
No, I'd call that speculative right now. What you can say, though, is that it shifts away from a contract the manufacturer controls — and that always creates a certain bias, naturally, in favor of the owner's own brands. I don't have the full picture, but my best read is that it's now an independent owner, and that, naturally, always opens up chances to come in with a good offer. Is that where we're strongest? No, not at the moment, but will we keep looking for opportunities? Yes.
Appreciate it.
Much appreciated. Our following question is from Susannah Ludwig at Bernstein. Go right ahead. Hello,
Good afternoon, and thanks for taking my questions. I have a couple about Oticon Reveal, specifically regarding what the hardware and software updates have involved. First, I guess, could you confirm what has been upgraded in the device's hardware compared with Oticon Intent, and in particular whether there is a new DSP chip? Then, I guess, regarding the key innovations you mentioned when it comes to the feedback and the gain, as well as the connectivity, are those driven by hardware improvements or by software improvements?
That's a fair question. I don't believe we're going to stand here and reveal the specific chip inside our hearing aids, but the overall system has essentially been re-engineered to deliver this new level of performance. We have had, and continue to have, a very energy-efficient architecture, and that is what makes success possible. It's a modern, powerful new DSP and AI system that lets us accomplish all of these impressive things without power consumption going through the roof. That is why we use a single integrated chip, so I think that's as much as we can say at this point without giving our competitors too much of a hand. Of course, there is a substantial change on the algorithm side, and that's where the genuine innovation lies — that's how we innovate the majority of signal processing today. It isn't really driven by hardware directly; it's driven by software, by computer applications or program applications that run. With the feedback system, it comes down heavily to the processor's speed and the algorithms behind it, while connectivity is far more tied to hardware. That has a great deal to do with antennas, signal strength and similar factors, which are typically more physical in nature — though algorithms have improved there as well.
I want to be sure I've got this straight — regarding your energy-efficient chip, it's the very same one that shipped in the Intent, correct? But at this point you've kind of restructured that, and the software updates have been made better — is that accurate?
I wouldn't say I gave a yes or a no there. I don't believe we're looking to sit here and reveal those specifics.
Thanks.
Thanks. Our following question is from Andjela Bozinovic at BNP Paribas. You have the floor.
Hello, good afternoon, and thanks for taking my questions. My first one is perhaps about the guidance. Earlier this year, when you gave a guide, you stressed that it was conservative, and now, when you upgrade a guide, you stress that the market assumptions are conservative. Could you explain how you're thinking about the upgraded guide, which indeed does imply significant market share gains on tougher comps and increased competitive pressure? My second question is just on trying to assess how excited you are about Oticon Reveal versus Oticon Zeal. Can you maybe share some insights on how you're thinking about uptake of this product overall, not only in 2026, but more the medium-term aspects versus Oticon Zeal? Thank you.
Glad to comment. First, Oticon Zeal had a soft launch in the second half of last year, near the end of the year, in selected countries. We got the US going during the year. We got VA going in May. Just having the full sequential half-year should drive additional share gains, and as I explained earlier using VA as an example, we definitely think there is more for Oticon Zeal to capture ahead of us. Reveal, of course, will refresh or bolster the existing momentum. Yes, we believe in share gains, and yes, we know we will likely face additional competitive launches too. We don't know what those are. That's also why we noted in our assumptions that this is, of course, factored into the guidance, which of course ultimately depends somewhat on what the competition brings, but it is in there, and it reflects the momentum. It's also because the group today has more than half in the Hearing Care business, which has somewhat less sensitivity to competitive launches, and therefore a stable momentum there, and that's the comfort. We still hold the same view of the market, and it's still, you could say, seen as slightly conservative, but political uncertainty persists.
The back half was 2% to 4%, exactly what we had assumed for the front half—and it ended up at 4%, not 2%. I'd still call that the largest swing factor for the second half, along with, naturally, gaining visibility into what competitors will bring; so far we've seen only a limited showing of that, just one of the three launches we assumed. If I got your question right, it followed a bit on the earlier one: how will the technology make its way into the portfolio? Naturally, there's a plan for the period ahead regarding how the Oticon Reveal platform will move into other form factors and styles, and likewise for Oticon Zeal, how that product concept will keep developing. That was a first version, and we see a long journey ahead for products built this way.
Appreciate it.
Thanks. Our following question is from Martinien Rula at Jefferies. You have the floor.
Good afternoon, everyone. Martinien here from Jefferies. I hope you can hear me clearly. I have two questions, if that works for you. First, on the potential contribution you'd anticipate from the new platform. The real question is this: given the massive acceleration in organic sales growth we've seen in the wholesale part of the business, it seems you proved conservative about what Zeal could achieve. So I was wondering whether that gap between what you initially envisioned for Zeal and its actual contribution to the business has influenced at all how you're now thinking about the commercial potential of the new platform? My second question concerns the group gross margin. Obviously, you now have Kind's contribution. Historically, the group's gross margin was expected to land between 76% and 77%. So I was wondering whether Kind's integration has changed at all how we should think about the group gross margin going forward, or not? Thank you.
Thanks a lot. I’m not completely certain I caught the entirety of your first question, but the new platform will definitely gain from Zeal’s momentum. Once again, we’ve opened fresh doors, and we truly view it as a portfolio. It’s an ideal fit for first-time users, it’s a solid fit for existing users, and some like one better than the other. I think the two work nicely together. I think that’s the straightforward answer. Regarding gross margin, we’re a little above, René?
I'd say with the gross margin running higher in the first half of the year, we're really pleased about the contribution from Kind, as you pointed out yourself, and also about an ASP contribution that you could call quite unique. And while we actually expect the second half of this year to show a high gross margin above 77% and perhaps even a touch higher than H1, it's a little early to make a fundamental change to our view of gross margin sitting at the high end of the 76% to 77% range. That's the way we see it today.
Appreciate it.
Thanks. We’ll take our final question from Falko Friedrichs at Deutsche Bank. Please go ahead. Yes,
Thanks. I have one remaining question about Diagnostics. Could you give us some additional detail regarding how that business performed in Q2? And do you feel confident that a more durable inflection point has now been reached for this business when it comes to growth? Thank you.
What I'd emphasize first is that beneath those figures, the real driver is instrument sales, which are rising. Service and calibration, naturally, make up a steadier kind of business. Calibration occurs on a set schedule, and you require a given quantity of disposables to keep operations running—but the timing of deciding to upgrade an instrument or expand clinics is what matters. That's the encouraging sign we're seeing: something of a release of the many orders that had built up along with the uncertainty. You could trace it back to the political shift in Q2 of last year, which tended to put investment goods on hold somewhat, I'd say, across many categories. We do view it as the market loosening up to some degree. Could things stall once more? Certainly, if circumstances shift, but at present we sense the momentum is both healthy and firm. When projecting ahead, you obviously need to examine the prior year's growth rates quarter by quarter. Those too shifted or followed particular dynamics last year.
Thanks.
Thanks. That wraps up the Q&A portion. I'll hand things back to management now for any closing comments.
Thanks, Operator, and many thanks to all of you for being with us on this call. I realize there are a few folks waiting in the queue, but we'll get in touch with you individually so your questions can be handled offline. As we always do, we'll be traveling over the next few weeks, and we hope to see you out there. Enjoy the rest of your day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Demant A/S transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Demant A/S earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.